Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 50
Filter
1.
Biology (Basel) ; 12(5)2023 Apr 26.
Article in English | MEDLINE | ID: mdl-37237465

ABSTRACT

Proton-coupled oligopeptide transporters (POTs) are a fundamental part of the cellular transport machinery that provides plants, bacteria, and mammals with nutrition in the form of short peptides. However, POTs are not restricted to peptide transport; mammalian POTs have especially been in focus due to their ability to transport several peptidomimetics in the small intestine. Herein, we studied a POT from Clostridium perfringens (CPEPOT), which unexpectedly exhibited atypical characteristics. First, very little uptake of a fluorescently labelled peptide ß-Ala-Lys-AMCA, an otherwise good substrate of several other bacterial POTs, was observed. Secondly, in the presence of a competitor peptide, enhanced uptake of ß-Ala-Lys-AMCA was observed due to trans-stimulation. This effect was also observed even in the absence of a proton electrochemical gradient, suggesting that ß-Ala-Lys-AMCA uptake mediated by CPEPOT is likely through the substrate-concentration-driving exchange mechanism, unlike any other functionally characterized bacterial POTs.

2.
Haemophilia ; 28(2): 286-291, 2022 Mar.
Article in English | MEDLINE | ID: mdl-35014121

ABSTRACT

INTRODUCTION: von Willebrand disease (VWD) is the common bleeding disorder with a clinically relevant bleeding prevalence of 1:10,000. von Willebrand disease patients lack both von Willebrand factor (VWF) and factor VIII (FVIII), which are critical for normal haemostasis. The conventional treatment for VWD includes desmopressin and replacement therapy with plasma derived FVIII with VWF concentrates or recombinant VWF. Development of alloantibodies is a rare occurrence, there is a paucity in the literature of treatment modalities in these patients. Not many reports are available in literature on the efficacy of emicizumab in VWD patients with or without alloantibodies to VWF. AIM: To do systematic review of literature on emicizumab in VWD and report our experience of emicizumab in two patients of VWD METHODS: We used electronic search engines till May 2021 in 'Google scholar' and 'PubMed', to collect the case reports or case series on use of emicizumab for management of VWD. Two of our severe VWD patients were successfully treated with emicizumab. A systematic review was performed and the results discussed. RESULTS: The electronic search revealed six case reports using emicizumab for treatment of VWD. Two were in vitro studies and four in patients with VWD type 3 disease. In vitro studies and in VWD patients on emicizumab, showed improvement in thrombin generation and fibrin formation. Among four patients, three had alloantibodies to VWD and one was negative. All these patients were treated with emicizumab for 6-12 m. After starting emicizumab, none of them had spontaneous bleeding requiring treatment. During treatment with emicizumab, one patient had trauma-associated soft tissue hematoma, which was treated with rFVIIa and another patient had bleeding following dental exfoliation treated with Humate P. We treated two of our VWD patients one with and one without inhibitors with emicizumab after failure of other therapies. Both the patients showed marked improvement and continued to remain well and free of bleeding episodes. None of the patients had any thrombosis or thrombotic microangiopathy (TMA) during treatment with emicizumab. CONCLUSION: In conclusion, this review supports the safety and efficacy of emicizumab in type 3 VWD patients with or without alloantibodies. Further large studies are required to confirm the safety and efficacy of emicizumab in VWD.


Subject(s)
Antibodies, Bispecific , von Willebrand Diseases , Antibodies, Bispecific/therapeutic use , Antibodies, Monoclonal, Humanized , Factor VIII , Humans , Isoantibodies , von Willebrand Diseases/complications , von Willebrand Diseases/drug therapy , von Willebrand Factor
3.
Protein Expr Purif ; 190: 105990, 2022 02.
Article in English | MEDLINE | ID: mdl-34637915

ABSTRACT

The human peptide transporter hPEPT1 (SLC15A1) is responsible for uptake of dietary di- and tripeptides and a number of drugs from the small intestine by utilizing the proton electrochemical gradient, and hence an important target for peptide-like drug design and drug delivery. hPEPT1 belongs to the ubiquitous major facilitator superfamily that all contain a 12TM core structure, with global conformational changes occurring during the transport cycle. Several bacterial homologues of these transporters have been characterized, providing valuable insight into the transport mechanism of this family. Here we report the overexpression and purification of recombinant hPEPT1 in a detergent-solubilized state. Thermostability profiling of hPEPT1 at different pH values revealed that hPEPT1 is more stable at pH 6 as compared to pH 7 and 8. Micro-scale thermophoresis (MST) confirmed that the purified hPEPT1 was able to bind di- and tripeptides respectively. To assess the in-solution oligomeric state of hPEPT1, negative stain electron microscopy was performed, demonstrating a predominantly monomeric state.


Subject(s)
Gene Expression , Peptide Transporter 1 , Hot Temperature , Humans , Hydrogen-Ion Concentration , Peptide Transporter 1/biosynthesis , Peptide Transporter 1/chemistry , Peptide Transporter 1/genetics , Peptide Transporter 1/isolation & purification , Protein Stability , Recombinant Proteins/biosynthesis , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/isolation & purification
4.
Enzyme Microb Technol ; 145: 109742, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33750535

ABSTRACT

Glucuronidated drug metabolites can be quantified from urine samples by first hydrolyzing conjugates with ß-glucuronidase (ß-GUS) and then separating free drug molecules by liquid chromatography and mass spectrometry detection (LC-MS). To improve the activity and specificity of various ß-GUS, we designed enzyme chimeras and generated site-saturation variants based on structural analyses, then screened them for improved activity on drug metabolites important to clinical and forensic drug-testing laboratories. Often, an increase of activity on one substrate of interest was countered by loss of activity against another, and there was no strong correlation of activity on standard ß-glucuronidase substrates to activity on recalcitrant drug glucuronides. However, we discovered a chimera of two enzymes from different species of Aspergillus that displays a 27 % increase in activity on morphine-3-glucuronide than the parent proteins. Furthermore, mutations in the M-loop, which is a loop near the active site, resulted in numerous variants with dramatically increased rates of hydrolysis on drug glucuronides. Specifically, the M-loop variant Q451D/A452E of a ß-GUS from Brachyspira pilosicoli has a 50-fold and 25-fold increase in activity on the recalcitrant substrates codeine-6-glucuronide and dihydrocodeine-6-glucuronide, respectively, compared to the parent enzyme.


Subject(s)
Glucuronidase , Hydrolases , Brachyspira , Chromatography, Liquid , Glucuronidase/genetics , Glucuronides , Hydrolysis
5.
Science ; 371(6535)2021 03 19.
Article in English | MEDLINE | ID: mdl-33737461

ABSTRACT

Interleukin-10 (IL-10) is an immunoregulatory cytokine with both anti-inflammatory and immunostimulatory properties and is frequently dysregulated in disease. We used a structure-based approach to deconvolute IL-10 pleiotropy by determining the structure of the IL-10 receptor (IL-10R) complex by cryo-electron microscopy at a resolution of 3.5 angstroms. The hexameric structure shows how IL-10 and IL-10Rα form a composite surface to engage the shared signaling receptor IL-10Rß, enabling the design of partial agonists. IL-10 variants with a range of IL-10Rß binding strengths uncovered substantial differences in response thresholds across immune cell populations, providing a means of manipulating IL-10 cell type selectivity. Some variants displayed myeloid-biased activity by suppressing macrophage activation without stimulating inflammatory CD8+ T cells, thereby uncoupling the major opposing functions of IL-10. These results provide a mechanistic blueprint for tuning the pleiotropic actions of IL-10.


Subject(s)
Interleukin-10/chemistry , Interleukin-10/metabolism , Animals , Binding Sites , CD8-Positive T-Lymphocytes/immunology , Cell Line , Cryoelectron Microscopy , Cytokines/metabolism , Directed Molecular Evolution , Humans , Inflammation , Interleukin-10/agonists , Interleukin-10 Receptor alpha Subunit/chemistry , Interleukin-10 Receptor alpha Subunit/metabolism , Interleukin-10 Receptor beta Subunit/chemistry , Interleukin-10 Receptor beta Subunit/metabolism , Macrophage Activation , Mice , Models, Molecular , Monocytes/immunology , Monocytes/metabolism , Myeloid Cells/immunology , Myeloid Cells/metabolism , Protein Binding , Protein Engineering , Protein Interaction Domains and Motifs , Protein Multimerization , STAT3 Transcription Factor/metabolism , Sepsis/immunology , Signal Transduction
6.
Int J Clin Pediatr Dent ; 13(3): 299-302, 2020.
Article in English | MEDLINE | ID: mdl-32903982

ABSTRACT

AIM: To create awareness about rare clotting disorders in children and to highlight the different dental treatment approaches that can be used while planning the management in such cases. BACKGROUND: A prerequisite for successful wound healing is achieving good hemostasis by effective vascular spasm, platelet plug formation, and finally blood coagulation. In the general population, postoperative bleeding after dental treatment is self-limiting. However, a certain segment of the population does suffer from inherited bleeding and clotting disorders, where in standard invasive dental procedures can trigger bleeding episodes, which could be life-threatening in absence of the requisite precautionary measures being followed. CASE DESCRIPTION: One such condition is congenital factor XIII deficiency, a rare autosomal recessive disease usually associated with early onset of serious or life-threatening bleeding episodes, such as, intracranial hemorrhage or umbilical cord bleeding. This case series details the complete dental management of three children suffering from factor XIII deficiency. CONCLUSION: Factor XIII is a rare coagulation cascade, and by this case series, complete dental treatment varying from noninvasive to be kept under observation to invasive dental extraction and fracture reduction was carried out with the hematologists consultations. CLINICAL SIGNIFICANCE: This case series creates awareness about this rare condition and the need for a multidisciplinary approach involving dentists and hematologists in the effective management of such patients. HOW TO CITE THIS ARTICLE: Pai NG, Mehta LK, Padhye NM, et al. Dental Management of Factor XIII Deficiency Patients: A Case Series. Int J Clin Pediatr Dent 2020;XX(X):1-4.

7.
Sci Rep ; 9(1): 4019, 2019 03 11.
Article in English | MEDLINE | ID: mdl-30858420

ABSTRACT

The full length human histone 3 lysine 4 demethylase KDM5B (PLU-1/Jarid1B) has been studied using Hydrogen/Deuterium exchange mass spectrometry, homology modelling, sequence analysis, small angle X-ray scattering and electron microscopy. This first structure on an intact multi-domain Jumonji histone demethylase reveal that the so-called PLU region, in the central region of KDM5B, has a curved α-helical three-dimensional structure, that acts as a rigid linker between the catalytic core and a region comprising four α-helices, a loop comprising the PHD2 domain, two large intrinsically disordered loops and the PHD3 domain in close proximity. The dumbbell shaped and curved KDM5B architecture observed by electron microscopy is complementary to the nucleosome surface and has a striking overall similarity to that of the functionally related KDM1A/CoREST complex. This could suggest that there are similarities between the demethylation mechanisms employed by the two histone 3 lysine 4 demethylases at the molecular level.


Subject(s)
Jumonji Domain-Containing Histone Demethylases/chemistry , Nuclear Proteins/chemistry , Repressor Proteins/chemistry , Co-Repressor Proteins/chemistry , Demethylation , Histone Demethylases/chemistry , Humans , Nerve Tissue Proteins/chemistry , Protein Domains
8.
Biochem Biophys Res Commun ; 495(2): 1738-1743, 2018 01 08.
Article in English | MEDLINE | ID: mdl-29208467

ABSTRACT

The human proton coupled folic acid transporter PCFT is the major import route for dietary folates. Mutations in the gene encoding PCFT cause hereditary folic acid malabsorption, which manifests itself by compromised folate absorption from the intestine and also in impaired folate transport into the central nervous system. Since its recent discovery, PCFT has been the subject of numerous biochemical studies aiming at understanding its structure and mechanism. One major focus has been its oligomeric state, with some reports supporting oligomers and others a monomer. Here, we report the overexpression and purification of recombinant PCFT. Following detergent screening, n-Dodecyl ß-D-maltoside (DDM) and lauryl maltose neopentyl glycol (LMNG) were chosen for further work as they exhibited the most optimal solubilization. We found that purified detergent solubilized PCFT was able to bind folic acid, thus indicating a functionally active protein. Size exclusion chromatography showed that PCFT in DDM was polydisperse; the LMNG preparation was clearly monodisperse but with shorter retention time than the major DDM peak. To assess the oligomeric state negative stain electron microscopy was performed which showed a particle with the size of a PCFT dimer.


Subject(s)
Proton-Coupled Folate Transporter/chemistry , Animals , Detergents , Folic Acid/metabolism , Glucosides , Glycols , Humans , Ligands , Microscopy, Electron , Models, Molecular , Protein Multimerization , Protein Structure, Quaternary , Proton-Coupled Folate Transporter/metabolism , Proton-Coupled Folate Transporter/ultrastructure , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Recombinant Proteins/ultrastructure , Sf9 Cells , Solubility , Spodoptera
9.
J Biol Chem ; 293(3): 1007-1017, 2018 01 19.
Article in English | MEDLINE | ID: mdl-29150447

ABSTRACT

Chloramphenicol (Cam) is a broad-spectrum antibiotic used to combat bacterial infections in humans and animals. Cam export from bacterial cells is one of the mechanisms by which pathogens resist Cam's antibacterial effects, and several different proteins are known to facilitate this process. However, to date no report exists on any specific transport protein that facilitates Cam uptake. The proton-coupled oligopeptide transporter (POT) YdgR from Escherichia coli is a prototypical member of the POT family, functioning in proton-coupled uptake of di- and tripeptides. By following bacterial growth and conducting LC-MS-based assays we show here that YdgR facilitates Cam uptake. Some YdgR variants displaying reduced peptide uptake also exhibited reduced Cam uptake, indicating that peptides and Cam bind YdgR at similar regions. Homology modeling of YdgR, Cam docking, and mutational studies suggested a binding mode that resembles that of Cam binding to the multidrug resistance transporter MdfA. To our knowledge, this is the first report of Cam uptake into bacterial cells mediated by a specific transporter protein. Our findings suggest a specific bacterial transporter for drug uptake that might be targeted to promote greater antibiotic influx to increase cytoplasmic antibiotic concentration for enhanced cytotoxicity.


Subject(s)
Chloramphenicol/metabolism , Escherichia coli Proteins/metabolism , Escherichia coli/metabolism , Membrane Transport Proteins/metabolism , Biological Transport , Escherichia coli/genetics , Escherichia coli Proteins/genetics , Membrane Transport Proteins/genetics , Mutagenesis, Site-Directed
10.
Nano Lett ; 17(6): 3396-3401, 2017 06 14.
Article in English | MEDLINE | ID: mdl-28474892

ABSTRACT

The current-phase relation (CPR) of a Josephson junction (JJ) determines how the supercurrent evolves with the superconducting phase difference across the junction. Knowledge of the CPR is essential in order to understand the response of a JJ to various external parameters. Despite the rising interest in ultraclean encapsulated graphene JJs, the CPR of such junctions remains unknown. Here, we use a fully gate-tunable graphene superconducting quantum intereference device (SQUID) to determine the CPR of ballistic graphene JJs. Each of the two JJs in the SQUID is made with graphene encapsulated in hexagonal boron nitride. By independently controlling the critical current of the JJs, we can operate the SQUID either in a symmetric or asymmetric configuration. The highly asymmetric SQUID allows us to phase-bias one of the JJs and thereby directly obtain its CPR. The CPR is found to be skewed, deviating significantly from a sinusoidal form. The skewness can be tuned with the gate voltage and oscillates in antiphase with Fabry-Pérot resistance oscillations of the ballistic graphene cavity. We compare our experiments with tight-binding calculations that include realistic graphene-superconductor interfaces and find a good qualitative agreement.

11.
Res Microbiol ; 168(5): 443-449, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28214542

ABSTRACT

Proton-dependent oligopeptide transporters (POTs) are secondary active transporters found in all kingdoms of life. POTs utilize the proton electrochemical gradient for the uptake of nutrient dipeptides and tripeptides. The human POT hPepT1 is known to transport a number of drugs. As part of ongoing studies on substrate specificities of POTs from Escherichia coli, our aim in this study was to investigate whether bacterial POTs could also transport these drugs. For this, we selected the common orally administered drugs sulpiride, bestatin, valacyclovir, ampicillin and oseltamivir, that are all transported by hPepT1. The transport of these drugs was evaluated using the prototypical POT YdgR from E. coli. The transport studies were pursued through combining cell-based assays with liquid chromatography-tandem mass spectrometric (LC-MS/MS) analysis. These investigations revealed that YdgR from E. coli is able to transport five (sulpiride, bestatin, valacyclovir, ampicillin and oseltamivir) drugs. Furthermore, cells not overexpressing YdgR were also able to transport these drugs in a POT-like manner. Orthologues of YdgR are found in several species in the gut microbiome; hence, our findings could have implications for further understanding about the interaction between gut microbes and orally administered drugs.


Subject(s)
Escherichia coli Proteins/metabolism , Escherichia coli/metabolism , Membrane Transport Proteins/metabolism , Peptide Transporter 1/metabolism , Pharmaceutical Preparations/metabolism , Acyclovir/analogs & derivatives , Acyclovir/metabolism , Biological Transport , Escherichia coli Proteins/genetics , Gastrointestinal Microbiome/drug effects , Humans , Membrane Transport Proteins/genetics , Oligopeptides/metabolism , Peptide Transporter 1/genetics , Protons , Substrate Specificity , Sulpiride/metabolism , Valacyclovir , Valine/analogs & derivatives , Valine/metabolism
12.
J Mol Microbiol Biotechnol ; 26(5): 312-9, 2016.
Article in English | MEDLINE | ID: mdl-27438044

ABSTRACT

Peptide transport in living organisms is facilitated by either primary transport, hydrolysis of ATP, or secondary transport, cotransport of protons. In this study, we focused on investigating the ligand specificity of the Neisseria meningitidis proton-coupled oligopeptide transporter (NmPOT). It has been shown that the gene encoding this transporter is upregulated during infection. NmPOT conformed to the typical chain length preference as observed in prototypical transporters of this family. In contrast to prototypical transporters, it was unable to accommodate a positively charged peptide residue at the C-terminus position of the substrate peptide. Sequence analysis of the active site of NmPOT displayed a distinctive aromatic patch, which has not been observed in any other transporters from this family. This aromatic patch may be involved in providing NmPOT with its atypical preferences. This study provides important novel information towards understanding how these transporters recognize their substrates.


Subject(s)
Membrane Transport Proteins/metabolism , Neisseria meningitidis/enzymology , Neisseria meningitidis/metabolism , Oligopeptides/metabolism , Proton Pumps/metabolism , Symporters/metabolism , Catalytic Domain , Membrane Transport Proteins/chemistry , Membrane Transport Proteins/genetics , Models, Molecular , Protein Conformation , Proton Pumps/chemistry , Proton Pumps/genetics , Substrate Specificity , Symporters/chemistry , Symporters/genetics
13.
J Biol Chem ; 290(50): 29931-40, 2015 Dec 11.
Article in English | MEDLINE | ID: mdl-26483552

ABSTRACT

Proton-coupled oligopeptide transporters (POTs) couple the inward transport of di- or tripeptides with an inwardly directed transport of protons. Evidence from several studies of different POTs has pointed toward involvement of a highly conserved sequence motif, E1XXE2RFXYY (from here on referred to as E1XXE2R), located on Helix I, in interactions with the proton. In this study, we investigated the intracellular substrate accumulation by motif variants with all possible combinations of glutamate residues changed to glutamine and arginine changed to a tyrosine, the latter being a natural variant found in the Escherichia coli POT YjdL. We found that YjdL motif variants with E1XXE2R, E1XXE2Y, E1XXQ2Y, or Q1XXE2Y were able to accumulate peptide, whereas those with E1XXQ2R, Q1XXE2R, or Q1XXQ2Y were unable to accumulate peptide, and Q1XXQ2R abolished uptake. These results suggest a mechanism that involves swapping of an intramotif salt bridge, i.e. R-E2 to R-E1, which is consistent with previous structural studies. Molecular dynamics simulations of the motif variants E1XXE2R and E1XXQ2R support this mechanism. The simulations showed that upon changing conformation arginine pushes Helix V, through interactions with the highly conserved FYING motif, further away from the central cavity in what could be a stabilization of an inward facing conformation. As E2 has been suggested to be the primary site for protonation, these novel findings show how protonation may drive conformational changes through interactions of two highly conserved motifs.


Subject(s)
Amino Acid Motifs , Membrane Transport Proteins/metabolism , Oligopeptides/metabolism , Salts/chemistry , Amino Acid Sequence , Membrane Transport Proteins/chemistry , Models, Molecular , Molecular Sequence Data , Protein Conformation , Protons , Sequence Homology, Amino Acid
14.
Nat Nanotechnol ; 10(9): 761-4, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26214253

ABSTRACT

Hybrid graphene-superconductor devices have attracted much attention since the early days of graphene research. So far, these studies have been limited to the case of diffusive transport through graphene with poorly defined and modest-quality graphene/superconductor interfaces, usually combined with small critical magnetic fields of the superconducting electrodes. Here, we report graphene-based Josephson junctions with one-dimensional edge contacts of molybdenum rhenium. The contacts exhibit a well-defined, transparent interface to the graphene, have a critical magnetic field of 8 T at 4 K, and the graphene has a high quality due to its encapsulation in hexagonal boron nitride. This allows us to study and exploit graphene Josephson junctions in a new regime, characterized by ballistic transport. We find that the critical current oscillates with the carrier density due to phase-coherent interference of the electrons and holes that carry the supercurrent caused by the formation of a Fabry-Pérot cavity. Furthermore, relatively large supercurrents are observed over unprecedented long distances of up to 1.5 µm. Finally, in the quantum Hall regime we observe broken symmetry states while the contacts remain superconducting. These achievements open up new avenues to exploit the Dirac nature of graphene in interaction with the superconducting state.

15.
Int J Biochem Cell Biol ; 55: 311-7, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25261786

ABSTRACT

Proton-coupled oligopeptide transporters (POTs) utilize an electrochemical proton gradient to accumulate peptides in the cytoplasm. Changing the highly conserved active-site Lys117 in the Escherichia coli POT YjdL to glutamine resulted in loss of ligand affinity as well as inability to distinguish between a dipeptide ligand and the corresponding dipeptide amide. The radically changed pH(Bulk) profiles of Lys117Gln and Lys117Arg mutants indicate an important role of Lys117 in facilitating protonation of the transporter; a notion that is supported by the close proximity of Lys117 to the conserved ExxERFxYY POT motif previously shown to be involved in proton translocation. These results point toward a novel dual role of Lys117 in direct or indirect interaction with both proton and peptide.


Subject(s)
Escherichia coli Proteins/metabolism , Lysine/metabolism , Membrane Transport Proteins/metabolism , Oligopeptides/metabolism , Protons , Amino Acid Motifs/genetics , Amino Acid Sequence , Binding Sites/genetics , Biological Transport/genetics , Cell Membrane/metabolism , Conserved Sequence/genetics , Escherichia coli Proteins/chemistry , Escherichia coli Proteins/genetics , Glutamine/chemistry , Glutamine/genetics , Glutamine/metabolism , Kinetics , Lysine/chemistry , Lysine/genetics , Membrane Transport Proteins/chemistry , Membrane Transport Proteins/genetics , Models, Molecular , Molecular Sequence Data , Mutation, Missense , Oligopeptides/chemistry , Protein Binding , Protein Structure, Tertiary , Sequence Homology, Amino Acid , Substrate Specificity
16.
FEBS Lett ; 588(4): 560-5, 2014 Feb 14.
Article in English | MEDLINE | ID: mdl-24440353

ABSTRACT

Proton-coupled oligopeptide transporters (POTs) are secondary active transporters that facilitate di- and tripeptide uptake by coupling it to an inward directed proton electrochemical gradient. Here the substrate specificities of Escherichia coli POTs YdgR, YhiP and YjdL were investigated by means of a label free transport assay using the hydrophilic pH sensitive dye pyranine and POT overexpressing E. coli cells. The results confirm and extend the functional knowledge on E. coli POTs. In contrast to previous assumptions, alanine and trialanine appears to be substrates of YjdL, albeit poor compared to dipeptides. Similarly tetraalanine apparently is a substrate of both YdgR and YhiP.


Subject(s)
Escherichia coli Proteins/metabolism , Escherichia coli , Membrane Transport Proteins/metabolism , Amino Acid Substitution , Dipeptides/chemistry , Dipeptides/metabolism , Escherichia coli Proteins/chemistry , Escherichia coli Proteins/genetics , Hydrogen-Ion Concentration , Membrane Transport Proteins/chemistry , Membrane Transport Proteins/genetics , Protein Transport , Substrate Specificity
17.
Indian J Pharmacol ; 43(2): 197-9, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21572658

ABSTRACT

OBJECTIVE: To assess the anticataleptic and antiepileptic activity of leaves of Mucuna pruriens in albino rats. MATERIALS AND METHODS: Haloperidol-induced catalepsy (HIC), maximum electro-shock (MES) method, pilocarpine-induced Status epilepticus (PISE) and single-dose effect of M. pruriens were employed. RESULTS: M. pruriens (100 mg/kg) had significant anticataleptic and antiepileptic activity in HIC, MES, and PISE. CONCLUSIONS: M. pruriens extract has the potential to be an anticataleptic and antiepileptic drug. Dopamine and 5-HT may have a role in such activity.

18.
J Med Chem ; 53(20): 7327-36, 2010 Oct 28.
Article in English | MEDLINE | ID: mdl-20882962

ABSTRACT

Several antifolates, including trimethoprim (TMP) and a series of propargyl-linked analogues, bind dihydrofolate reductase from Bacillus anthracis (BaDHFR) with lower affinity than is typical in other bacterial species. To guide lead optimization for BaDHFR, we explored a new approach to determine structure-activity relationships whereby the enzyme is altered and the analogues remain constant, essentially reversing the standard experimental design. Active site mutants of the enzyme, Ba(F96I)DHFR and Ba(Y102F)DHFR, were created and evaluated with enzyme inhibition assays and crystal structures. The affinities of the antifolates increase up to 60-fold with the Y102F mutant, suggesting that interactions with Tyr 102 are critical for affinity. Crystal structures of the enzymes bound to TMP and propargyl-linked inhibitors reveal the basis of TMP resistance and illuminate the influence of Tyr 102 on the lipophilic linker between the pyrimidine and aryl rings. Two new inhibitors test and validate these conclusions and show the value of the technique for providing new directions during lead optimization.


Subject(s)
Anti-Bacterial Agents/chemical synthesis , Bacillus anthracis/enzymology , Biphenyl Compounds/chemical synthesis , Folic Acid Antagonists/chemical synthesis , Models, Molecular , Pyrimidines/chemical synthesis , Tetrahydrofolate Dehydrogenase/genetics , Alkynes/chemical synthesis , Alkynes/chemistry , Amino Acid Sequence , Anti-Bacterial Agents/chemistry , Biphenyl Compounds/chemistry , Catalytic Domain , Crystallography, X-Ray , Drug Resistance, Bacterial , Folic Acid Antagonists/chemistry , Hydrogen Bonding , Molecular Sequence Data , Mutagenesis, Site-Directed , Mutation , Protein Binding , Protein Conformation , Pyrimidines/chemistry , Static Electricity , Structure-Activity Relationship , Tetrahydrofolate Dehydrogenase/chemistry
19.
Int J Gynaecol Obstet ; 98(3): 285-90, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17617415

ABSTRACT

PURPOSE: We conducted a survey to determine availability of emergency obstetric care (EmOC) and to provide data for advocating for improved maternal and newborn health in Uganda. METHODS: The survey, covering 54 districts and 553 health facilities, assessed availability of EmOC signal functions, documented maternal deaths and the related causes. Three levels of health facilities were covered. FINDINGS: Few health units had running water; electricity or a functional operating theater. Yet having these items had a protective effect on maternal deaths as follows: theater (OR 0.56, P<0.0001); electricity (OR 0.39, P<0.0001); laboratory (OR 0.71, P<0.0001) and staffing levels (midwives) OR 0.20, P<0.0001. The availability of midwives had the highest protective effect on maternal deaths, reducing the case fatality rate by 80%. Further, most (97.2%) health facilities expected to offer basic EmOC, were not doing so. This is the likely explanation for the high health facility-based maternal death rate of 671/100,000 live births in Uganda. CONCLUSION: Addressing health system issues, especially human resources, and increasingaccess to EmOC could reduce maternal mortality in Uganda and enable the country to achieve the Millennium Development Goal (MDG).


Subject(s)
Community Health Centers/trends , Maternal Health Services/standards , Maternal Mortality/trends , Obstetric Labor Complications/mortality , Community Health Centers/statistics & numerical data , Emergency Service, Hospital/statistics & numerical data , Emergency Service, Hospital/trends , Female , Health Care Surveys , Health Promotion/trends , Health Services Accessibility , Homeodomain Proteins , Humans , Mortality/trends , Obstetric Labor Complications/therapy , Pregnancy , Pregnancy Outcome , Uganda/epidemiology
20.
Int J Gynaecol Obstet ; 98(3): 271-7, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17604032

ABSTRACT

INTRODUCTION: The Women's Right to Life and Health Project contributes to Nepal's National Safe Motherhood Program and maternal mortality reduction efforts by working to improve the availability, quality and utilization of emergency obstetric care services in public health facilities. METHODS: The project upgraded 8 existing public health facilities through infrastructure, equipment, training, data collection, policy advocacy, and community information activities. The total cost of the project was approximately US$1.6 million. RESULTS: In 5 years, 3 comprehensive and 4 basic emergency obstetric care (EmOC) facilities were established in an area where adequate EmOC services were previously lacking. From 2000 to 2004, met need for EmOC improved from 1.9 to 16.9%; the proportion of births in EmOC project facilities increased from 3.8 to 8.3%; and the case fatality rate declined from 2.7 to 0.3%. DISCUSSION: While the use of maternity services is still low in Nepal, improving availability and quality of EmOC together with community empowerment can increase utilization by women with complications, even in low-resource settings. Partnerships with government and donors were key to the project's success. Similar efforts should be replicated throughout Nepal to expand the availability of essential life-saving services for pregnant women.


Subject(s)
Emergency Service, Hospital , Health Personnel/education , Maternal Health Services/organization & administration , Obstetric Labor Complications/prevention & control , Community Health Services , Community Participation , Developing Countries , Female , Health Promotion/organization & administration , Humans , Inservice Training , Maternal Welfare , Midwifery/education , Nepal , Pregnancy , Women's Health
SELECTION OF CITATIONS
SEARCH DETAIL
...